Is it sufficient to evaluate bone marrow involvement in newly diagnosed lymphomas using $^{18}$F-FDG PET/CT and/or routine iliac crest biopsy? A new approach of PET/CT-guided targeted bone marrow biopsy

Bing Hao†, Long Zhao†, Na-na Luo, Dan Ruan, Yi-zhen Pang, Wei Guo, Hao Fu, Xiu-yu Guo, Zuo-ming Luo, Jing Wu, Hao-jun Chen, Hua Wu and Long Sun*

Abstract

Background: To investigate whether PET/CT-guided bone marrow biopsy adds complementary information for evaluation of bone marrow involvement (BMI) in newly diagnosed lymphomas.

Methods: Patients with newly diagnosed lymphomas that received both $^{18}$F-FDG PET/CT and bone marrow biopsy (BMB) were included in this retrospective study. PET/CT classification of bone lesions was classified as isolated, multifocal (2 lesions or more), diffuse (homogeneous uptake of the entire axial skeleton), or negative. BMBs included PET/CT-guided targeted BMB and/or the routine unilateral iliac crest biopsy. Of 34 patients with focal lesions on PET/CT scan, 30 received both PET/CT-guided targeted BMB and iliac crest biopsy, and 4 patients received targeted biopsy without iliac crest biopsy. The final diagnosis of BMI depends on BMB results.

Results: A total of 299 patients with lymphomas were included. PET/CT classification of bone lesions was isolated (16/5.4%), multifocal (67/22.4%), diffuse (52/17.4%), and negative (164/54.8%). If only positive iliac crest biopsy was considered as the reference standard, the sensitivity of $^{18}$F-FDG PET/CT for identifying focal and diffuse BMI was 48 and 56%, respectively, and the respective specificities were 70 and 83%. Three of 30 patients (10.0%) with focal lesions on PET/CT were confirmed to be false-positive by targeted BMB, and 25 of 30 patients (83.3%) with focal lesions on PET/CT were confirmed as false-negative by iliac crest biopsy.

Conclusion: It is insufficient to evaluate BMI in newly diagnosed lymphomas using both $^{18}$F-FDG PET/CT and routine iliac crest biopsy. $^{18}$F-FDG PET/CT imaging should be performed before BMB. In focal bone lesions, PET/CT-guided targeted BMB may complement the results of possible false-positive PET/CT and false-negative iliac crest biopsy findings. However, in diffuse and negative lesions, iliac crest biopsy cannot be safely omitted.

Keywords: Lymphomas, Bone marrow involvement, $^{18}$F-FDG PET/CT, Bone marrow biopsy
Background

Lymphomas are malignant neoplasms characterized by the proliferation of cells native to the lymphoid tissue. In 2015, an estimated 88,200 people will be diagnosed with lymphomas, and there will be approximately 52,100 deaths due to the disease in China [1]. Lymphoma subtype and stage affect therapeutic decisions and prognosis. Thus, accurate assessment of lymphoma patients at initial presentation is necessary for good outcomes.

Bone marrow (BM) is an important extent site, which occurs in 5–15% of Hodgkin lymphomas (HLs), and 20–40% of non-Hodgkin lymphomas (NHLs), depending on the histological subtype [2, 3]. The evaluation of BM status is of critical importance in newly diagnosed lymphomas, as it is stage, diagnosis, and if prolonged chemotherapy or radiotherapy may be required.

According to the National Comprehensive Cancer Network (NCCN) guidelines for HL and NHL, routine iliac crest biopsy is essential in all lymphomas where treatment is considered, and is the gold standard for bone marrow staging. Unfortunately, results are subject to sampling error, especially focal bone lesions, which may lead to false-negative iliac crest biopsy results. Previous studies have demonstrate bilateral core biopsies can improves the diagnostic yield, ranging between 10 and 60% [4–6], however, an additional biopsy means more risk of complications such as bleeding, pain, and anxiety [7, 8].

There is debate about whether 18F-FDG PET/CT scanning can replace routine iliac crest biopsy [9–13]. The Lugano Classification [14] has noted that 18F-FDG PET/CT is highly sensitive for BMI which may complement the results of routine iliac crest biopsy, and that is has potential for accurate evaluation of BMI in HL and diffuse large B-cell lymphoma (DLBCL). El-Galaly et al. [15] concluded that routine iliac crest biopsy is not required for evaluation of HL if 18F-FDG PET/CT is performed. However, the reference standard according to iliac crest biopsy for true BMI has been questioned [16], since other diseases such as benign conditions or other malignancies can also generate false-positive PET/CT findings [17, 18]. Lim et al. [19] reported that iliac crest biopsy is only needed for DLBCL if the PET/CT finding is negative. The use of PET/CT for evaluation of other subtypes is also controversial. Nevertheless, false-positive PET/CT and false-negative routine iliac crest biopsy results will alter the bone staging of lymphomas. Thus, positive PET/CT findings require histological confirmation, with targeted biopsy preferred to other methods [20, 21].

In our previous study [22], PET/CT-guided targeted BMB was shown to be a safe and effective technique for the evaluation of advanced lung cancer with metastatic bone tumors. However, there are no studies examining the utility of PET/CT-guided targeted BMB, rather than iliac crest biopsy, for bone staging in newly diagnosed lymphomas. The aim of this study was to investigate whether PET/CT-guided targeted BMB adds complementary information for the evaluation of BMI in newly diagnosed lymphomas.

Methods

Patients

We retrospectively reviewed the records of patients with a diagnosis of lymphoma treated at our center from January 2012 to January 2018. Patients were identified through the electronic medical records and pathological reporting systems. Patients were included in this study if 18F-FDG PET/CT-guided targeted BMB or iliac crest biopsy were performed as part of the initial clinical lymphoma staging, and no other malignancy was present.

Patients did not receive chemotherapy prior to 18F-FDG PET/CT scanning, and PET/CT scans were performed within 7 days before or after BMB. Patients were staged according to the Ann Arbor classification. BMI was confirmed based on histological evaluation of biopsy results.

PET/CT technique and imaging

Patients were asked to fast for 4–6 h before 18F-FDG PET/CT scanning. Blood glucose levels were confirmed to be within a maximum value of 120 mg/dL. Intravenous injection of the 18F-FDG tracer was administered at a dosage of 0.1–0.2 mCi/kg. Thereafter, the patient rested for 20 min and was encouraged to drink water. A low-dose CT scan from the head to the proximal femur was performed first, with parameters of 110 kV, 110 mA, a tube rotation time of 0.5 s, and 3.3-mm section thickness, which was matched to the PET section thickness. The second scan was immediately followed by a PET scan of the identical transverse field of view. Emission time was acquired for 3 min per table position.

Data acquisition by an integrated PET/CT system (Discovery STE; GE Medical Systems, Milwaukee, WI, USA) was performed within 60 min of tracer injection. PET/CT image data sets were reconstructed iteratively by applying the CT data for attenuation correction, and co-registered images were displayed on an ADW4.3 or ADW4.6 workstation.

PET/CT images were carefully reviewed by 2 senior nuclear medicine physicians. Most indolent lymphomas demonstrate an increased 18F-FDG uptake, but the degree of 18F-FDG uptake is lower than aggressive lymphomas. If used the positive finding as the uptake over than liver, it may underestimate BMI of indolent lymphomas. 18F-FDG uptake of some indolent lymphomas actually was lower than liver, especially in diffuse BMI.

Positive PET/CT findings were based on the visual assessment of 18F-FDG uptake in the involved sites relative to that of the mediastinum. PET/CT-assessed bone lesions
were characterized as isolated, multifocal, diffuse, and negative. PET/CT-guided targeted BMB was performed to determine the diagnosis and bone staging of lymphomas.

**BMB**

Two methods of BMB were performed: 1) routine unilateral iliac crest biopsy and 2) PET/CT-guided targeted bone marrow biopsy.

Unilateral iliac crest BMB was routinely in newly diagnosed lymphoma patients performed before any treatment was administered. One sample was obtained for each patient, and lengths of the samples were 1.0 cm.

PET/CT-guided targeted BMB was performed by 1 board certified nuclear medicine physician using the same PET/CT scanner on a separate day to reduce the radiation dose to the operator. 18F-FDG PET/CT fused images were used to determine the appropriate puncture site with high FDG uptake, and the biopsy needle was introduced stepwise under fused PET/CT image and CT guidance. An 11G (BMN-B, SA Medical & Plastic Instruments Co., Ltd., Shanghai, China) biopsy needle was used. One or two samples were obtained for each patient, and the lengths of samples all were 1.5 or 2.2 cm.

All patients were kept for observation for at least 2 h after the biopsy procedure. The BMB specimens were analyzed by morphological and immunohistochemical studies. The pathological results of all BMBs were validated by review of the individual pathology reports.

**Reference standard**

Three reference standards for true BMI were used: 1) the iliac crest biopsy; 2) both focal skeletal PET/CT lesions and positive iliac crest biopsy; 3) PET/CT-guided targeted BMB.

**Statistical analysis and ethics**

Median and range were reported for continuous variables, and counts and percentages for categorical variables. Clopper-Pearson exact confidence limits were calculated for sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. Differences between PET/CT-guided targeted BMB and routine BMB were analyzed using Fisher exact test. All statistical analysis was performed using SPSS, version 23, and MedCalc, version 12.2.1 software. The P value for statistical significance was set to P < .05. This retrospective evaluation of collected data was approved by the ethics committee of our institution. All patients gave their written informed consent prior to any procedures performed.

**Results**

**Inclusion criteria**

A total of 317 patients with lymphomas were identified and screened for eligibility. Twelve patients did not have
an iliac crest biopsy in the staging workup, and 6 pa-
tients had another coexisting malignancy, and were thus
excluded. Thus, 299 patients met the inclusion criteria
and were included in the analysis. Of 299 patients identi-
fied, 295 patients received an iliac crest biopsy, and 4 pa-
tients had only a targeted biopsy. Of the 295 patients
received an iliac crest biopsy, 30 patients with focal le-
ssions received both a targeted biopsy and the iliac crest
biopsy. Most of the suspicious lymphoma patients will
be recommended for PET/CT examination to further
diagnosis and differential diagnosis. It is difficult to get
definite lymphomas subtypes diagnosis before PET/CT
examination in daily clinical practice.

Study flow diagram is shown in Fig. 1.

Clinicopathological characteristics
The median age of patients in the study was 54.8 years
(range, 4–91 years), and the male: female ratio was 1:5.
The lymphoma subtypes were classified as HL, low-grade,
high-grade, NHL, unclassification, Richter transformation
and others. Patient characteristic are summarized in the
Table 1.

PET/CT classification of bone lesions in newly diagnosed
lymphomas
Abnormal skeletal FDG uptake was present in 135
patients (45.2%). Eighty-three of 135 had focal lesions (iso-
lated, 16; multifocal, 67). Of the 83 patients, 16 had
positive iliac crest biopsies; 52 of 135 had diffusely homo-
genous FDG uptake. Of the 52 patients, 22 had positive
iliac crest biopsies involving most of the axial skeleton.
Negative skeletal FDG uptake was present in 164 patients
(54.8%), of whom 17 had positive iliac crest biopsies. PET/
CT data are summarized in Table 2.

Diagnostic performance of 18F-FDG PET/CT and iliac crest
biopsy for determination of BMI
Results of the diagnostic performance of 18F-FDG PET/
CT and iliac crest biopsy for evaluating BMI are shown
in Table 3. If only positive iliac crest biopsy was consid-
ered the reference standard for true BMI, the sensitivity
and specificity of 18F-FDG PET/CT for detection of focal
bone lesions were 48% (95% confidence interval [CI]: 31
to 66%) and 70% (95% CI: 63 to 76%), respectively. The
PPV and NPV were 20% (95% CI: 12 to 31%) and 90%
(95% CI: 84 to 94%), respectively. The overall diagnostic
accuracy (the proportion of true-positive and true-nega-
tive results over the total number of tests performed)
was 67% (95% CI: 61 to 73%). For diffuse lesions, the
sensitivity and specificity were 56% (95% CI: 40 to 72%)
and 83% (95% CI: 77 to 88%), respectively. The PPV and
NPV were 42% (95% CI: 30 to 57%) and 90% (95% CI:
84 to 90%), respectively. The overall diagnostic accuracy
was 78% (95% CI: 72 to 83%).

If focal skeletal PET/CT lesions and positive iliac crest
biopsy were both considered as the reference standard
for true BMI, the sensitivity of focal bone lesions was
82% (95% CI: 71 to 88%) for PET/CT versus 34% (95%
CI: 25 to 45%) for iliac crest biopsy. The NPVs were 90%
(95% CI: 84 to 94%) for PET/CT versus 70% (95% CI: 63
to 76%) for iliac crest biopsy. The overall diagnostic ac-
curacy was 93% (95% CI: 89 to 96%) for PET/CT versus
74% (95% CI: 68 to 79%) for iliac crest biopsy. As for dif-
fuse lesions, the sensitivity was 75% (95% CI: 63 to 85%)
for PET/CT versus 57% (95% CI: 44 to 68%) for iliac

---

**Table 1** Clinicopathologic Characteristics of the Study Cohort (n = 299)

| Characteristic                  | No. of patients | %    |
|--------------------------------|-----------------|------|
| Study subject                  | 299             |      |
| Male: Female ratio             | 1.5             |      |
| Age, years                     |                 |      |
| median                         | 54.8            |      |
| range                          | 4–91            |      |
| PET-assessed skeletal pattern  |                 |      |
| Focal, isolated                | 16              | 5.4  |
| Focal, multiple                | 67              | 22.4 |
| Diffuse                        | 52              | 17.4 |
| Negative                       | 164             | 54.8 |
| Subtypes of lymphoma           |                 |      |
| Hodgkin lymphoma               | 25              | 8.4  |
| Low-grade Non-Hodgkin lymphoma | 68              | 22.7 |
| High-grade Non-Hodgkin lymphoma| 170             | 56.9 |
| Unclassification               | 17              | 5.7  |
| Richter transformation         | 5               | 1.7  |
| Others                         | 14              | 4.6  |

**Abbreviations:** NLP Nodular lymphocyte predominant, NS Nodular sclerosis lymphomas, MC Mixed cellularity, LR Lymphocyte-rich, DLBC Diffuse large B cell, PTC Peripheral T cell, BL Burkitt lymphoma, ACL Anaplastic large cell, MZ Marginal zone, MC Mantle cell, MALT Mucosa-associated lymphoid tissue, SLI/CLL Chronic lymphocytic leukemia/small lymphocytic lymphoma

---

**Table 2** Concordance Between Bone Marrow Biopsy and PET/CT Findings for Evaluation of Bone Marrow Disease (n = 295)

| Bone marrow involvement | Total |
|-------------------------|-------|
| +                       |       |
| PET focal bone lesions  | 16    | 63   | 79   |
| PET diffuse bone lesions| 22    | 30   | 52   |
| PET negative            | 17    | 147  | 164  |
| Total                   | 55    | 240  | 295  |

---

Hao et al. BMC Cancer (2018) 18:1192
Table 3  Sensitivity, Specificity, PPV, NPV, and Accuracy of the Iliac Crest Biopsy and PET/CT for Detection of Bone Marrow Disease in the 295 patients

| Diagnostic Modality | %  | 95%CI | %  | 95%CI |
|---------------------|----|-------|----|-------|
| **Bone Disease Defined Only by Positive Iliac crest biopsy (n = 55)** |
| **Iliac crest biopsy** |
| Focal |
| Sensitivity | N/A<sup>a</sup> |
| Specificity | N/A<sup>a</sup> |
| PPV | N/A<sup>a</sup> |
| NPV | N/A<sup>a</sup> |
| Accuracy | N/A<sup>a</sup> |
| **PET/CT** |
| Focal |
| Sensitivity | 48 | 31 to 66 |
| Specificity | 70 | 63 to 76 |
| PPV | 20 | 12 to 31 |
| NPV | 90 | 84 to 94 |
| Accuracy | 67 | 61 to 73 |
| **Bone Disease Defined Only by Positive Iliac crest biopsy and/or FDG-avid bone lesion (n = 148)** |
| **Iliac crest biopsy** |
| Focal |
| Sensitivity | 34 | 25 to 45 |
| Specificity | N/A<sup>b</sup> |
| PPV | N/A<sup>b</sup> |
| NPV | 70 | 63 to 76 |
| Accuracy | 74 | 68 to 79 |
| **PET/CT** |
| Focal |
| Sensitivity | 82<sup>†</sup> | 71 to 88 |
| Specificity | N/A<sup>b</sup> |
| PPV | N/A<sup>b</sup> |
| NPV | 90<sup>†</sup> | 84 to 94 |
| Accuracy | 93<sup>†</sup> | 89 to 96 |

Abbreviations: PET Positron emission tomography, CT Computed tomography, N/A Not applicable, NPV Negative predictive value, PPV Positive predictive value
<sup>†</sup>P < 0.05 for difference between the routine iliac crest biopsy and PET/CT for detection of bone marrow disease
<sup>a</sup>N/A because iliac crest biopsy is considered the gold standard in this analysis
<sup>b</sup>N/A because of missing reference for true positive

Table 4  18F-FDG avidity of Indolent lymphomas

| Indolent lymphomas subtype | N | 18F-FDG-avid | Negative | %<sup>18F-FDG-avid | Focal/Diffuse/Negative bone lesions |
|----------------------------|---|-------------|---------|------------------|----------------------------------|
| Follicular                 | 24 | 20          | 4       | 83.3             | 2/4/18                           |
| Marginal zone              | 10 | 9           | 1       | 90               | 1/6/3                            |
| MALT                       | 9  | 6           | 3       | 66.7             | 0/0/9                            |
| SLL/CLL                    | 12 | 9           | 3       | 75               | 2/4/6                            |
| Mantle cell                | 13 | 13          | 0       | 100              | 0/3/10                           |

Abbreviations: MALT Mucosa-associated lymphoid tissue, SLL/CLL Small lymphocytic lymphoma/chronic lymphocytic leukemia
The NPVs were 90% (95% CI: 84 to 94%) for PET/CT versus 83% (95% CI: 77 to 88%) for iliac crest biopsy. The overall diagnostic accuracy was 92% (95% CI: 89 to 95%) for PET/CT versus 86% (95% CI: 81 to 90%) for iliac crest biopsy.

PET/CT findings of indolent lymphomas
The main subtypes of indolent lymphomas were follicular, marginal zone, mucosa-associated lymphoid tissue (MALT), small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) and mantle cell lymphomas. The 18F-FDG avidity of this group of lymphomas was demonstrated in Table 4.

Differences of bone staging between PET/CT-guided targeted BMB and iliac crest biopsy for focal bone lesions
A comparison of the diagnostic performance between PET/CT-guided targeted BMB and iliac crest biopsy for the assessment of focal BM disease in the 30 patients is shown in Table 5. The diagnostic ability of targeted BMB was superior to that of iliac crest biopsy (sensitivity of 90.0% versus 16.7%, respectively, \( P < 0.05 \)). Three of 30 patients with a negative targeted biopsy were confirmed to have false-positive PET/CT findings, and the pathological results included 1 eosinophilic granuloma with fibrosis, 1 myelodysplastic syndrome (MDS) and 1 active bone marrow hyperplasia. Twenty-five of 30 patients with focal lesions on PET/CT scan were confirmed to have false-negative results of iliac crest biopsies. In addition, in 4 patients who had a targeted BMB without an iliac crest biopsy, the diagnosis and bone staging was established in a single procedure.

BMB related inflammatory response and complications
Forty-eight patients with focal lesions received PET/CT scan after BMB. In those patients, only 4(83.3%) patients had slightly \(^{18}\)F-FDG uptake in the puncture site, the degree of \(^{18}\)F-FDG uptake of puncture site is obviously lower than that of lesions of BM. The average time to perform a biopsy was 30 min. Slight bleeding and pain occurred in almost all patients who underwent a biopsy, but no serious complications were noted (Table 6).

Representative images are shown in Figs. 2, 3, 4, 5 and 6.

**Discussion**
To our knowledge, this study is the first to propose the notion that PET/CT-guided targeted BMB can add pathological confirmation of focal BMI in newly diagnosed lymphomas. Based on the data that \(^{18}\)F-FDG PET/CT overcomes deficiencies of iliac crest biopsy, targeted BMB has gradually become routine practice at our institution.

\(^{18}\)F-FDG PET/CT has been widely accepted for the evaluation of focal BMI of HL, without the need for routine iliac crest biopsy [14, 15]. However, its actual diagnostic value is difficult to determine because of scarce target biopsies, and only the iliac crest biopsy as a reference standard for true BMI may erroneously generate false-positive PET/CT and false-negative iliac crest biopsy results. Our results demonstrated that 1 of 2 patients with HL with focal bone lesions on PET/CT scan, together with a negative iliac crest biopsy, confirmed the false-positive PET/CT findings via a targeted biopsy. If all subtypes were included, in the 30 patients in whom a targeted biopsy and an iliac crest biopsy were performed, 3 of 30 patients who had a positive PET/CT findings were shown to have other BM diseases rather than lymphoma BMI by targeted biopsy. Therefore, although \(^{18}\)F-FDG PET/CT can easily detect the bone

### Table 5
| Pathological results | Total | \( P \) |
|----------------------|-------|--------|
|                      |       |        |
| **Target bone biopsy** \( n = 30 \) | 27 (90.0%) | 30 | < 0.05 |
|                      |       |        |
| **Routine iliac crest biopsy** \( n = 30 \) | 5 (16.7%) | 25 (83.3%) | 30 |

\(^{*}\) Negative results include one eosinophilic granuloma with fibrosis, one myelodysplastic syndrome (MDS) and one active bone marrow hyperplasia

\(^{‡}\) Fisher exact test

### Table 6
| Biopsy site | No. of biopsies | Biopsy procedure | Diagnosis Subtype | Other | Bone morphologic abnormalities on CT findings |
|-------------|----------------|------------------|------------------|-------|---------------------------------------------|
|             |                |                  |                  |       | No. of Yes | No. of No |
| Ilium       | 22             | 22               | 15               | 15    | 19 | 3 | 15 | 8 |
| Sacrum      | 6              | 6                | 5                | 4     | 6 | 0 | 1 | 5 |
| Ischium     | 3              | 3                | 3                | 3     | 3 | 0 | 1 | 1 |
| Rib         | 1              | 1                | 0                | 0     | 1 | 0 | 1 | 0 |
| Femur       | 2              | 2                | 2                | 2     | 2 | 0 | 1 | 1 |
| Total       | 34             | 34               | 25               | 24    | 31 | 3 | 19 | 15 |

\(^{a}\) Subtype means definite subtype diagnosis, such as diffuse large B cell lymphoma

\(^{b}\) Other include one eosinophilic granuloma with fibrosis, one myelodysplastic syndrome (MDS) and one active bone marrow hyperplasia
lesions, positive findings also required histological examination, even in cases of HL.

Adequate imaging is a prerequisite for performing a biopsy to establish a diagnosis. Advances in imaging techniques have contributed to the increasing use of image-guided percutaneous biopsy for the diagnosis of primary and secondary bone tumors [23, 24]. 18F-FDG PET/CT is the preferred method for determining the choice of biopsy site, as it is superior to other imaging methods [25]. Compared to a conventional CT-guided biopsy, the dual modality technique provides co-registered information about both the morphology and physiology of the proposed biopsy site, and can offer a target that exhibits increased FDG uptake [26]. In addition, whole body PET/CT allows visualization of the entire marrow and provides better visualization of poorly defined bone abnormalities than other modalities [27, 28]. In our study, 19 of 34 patients had no bone abnormalities on CT and were thus not suitable for CT-guided biopsy, while PET/CT identified an accurate biopsy site. Most importantly, the PET/CT classification of bone lesions of lymphomas is useful for determining the choice of biopsy. The pattern of skeletal FDG uptake was categorized as isolated, multifocal, diffuse, and negative. Our results also demonstrated 5 of

---

**Fig. 2** PET/CT classification of bone marrow involvement (maximum intensity projection images, MIP). a Isolated lesion in the left ilium (black arrow). b Multifocal lesions in bone marrow. c Diffuse lesions in axial skeleton. d Negative PET findings in bone marrow.

---

**Fig. 3** PET/CT-guided targeted bone marrow biopsy procedure. a-c 18F-FDG PET/CT findings. a The MIP image showed multifocal lesions in the region of bone and abdomen. b and c Axial CT image, axial PET/CT fusion image, showed high 18F-FDG uptake within the left ilium (white arrow), while no overt bony change was observed within the corresponding hypermetabolic region. d Procedure of biopsy target selection. e Puncture process using a 16G bone biopsy needle. f CT image showed the biopsy needle positioned within the left ilium lesion (white arrow). g Histological examination combined with immunohistochemical result confirmed a diagnosis of NHL (high-grade B cell lymphoma), suggesting further examination with C-MYC, Bcl-2, and Bcl-6 genetic testing.
68 patients (7.4%) with focal $^{18}$F-FDG–avid bone lesions in indolent lymphomas. Individual algorithms for evaluation of BMI should be performed for various bone lesions identified on PET/CT imaging. In general, failure to follow appropriate biopsy procedures may lead to inaccurate bone staging.

Currently, routine iliac crest biopsy is still the standard bone staging method for patients with newly diagnosed lymphomas [29]. However, it is well-known that the procedure is associated with low sensitivity in newly diagnosed lymphomas, especially those with focal BMI. In other words, a negative routine iliac crest biopsy cannot rule out the presence of BMI. Our results showed that PET/CT had a sensitivity of 48% in 79 patients with focal bone lesions. Sampling error, especially outside the iliac crest, may be major factor. Thus, it is preferable to use PET/CT-guided targeted BMB in the case of positive PET/CT findings to easily obtain representative tissue. First, a separate staging procedure adds time, cost, coordination of care, inconvenience, and an additional anesthetic risk [7, 30]. In the 34 patients in our study, 4 patients were simultaneously confirmed diagnosis and stage of lymphoma only through targeted BMB so that iliac crest biopsy could be avoided. Second, targeted biopsy avoided false-positive PET/CT findings in 3 of 34 patients in our study, which can result in inaccurate staging. Third, targeted biopsy was obviously superior to routine iliac crest biopsy in our study (sensitivity of 90.0% for targeted biopsy vs. 16.7% for iliac crest biopsy), and a false-negative iliac crest biopsy was avoided. In addition, we believe that targeted biopsy is a suitable reference standard to calculate the specificity of bone marrow $^{18}$F-FDG PET.

PET/CT-guided targeted BMB is a safe and feasible method for bone lesions [27, 31–33]. The preferred choice of puncture site for an individual patient depends on the size and location and local experience and expertise. In our study, the relatively safer puncture site that is suspicious BMI on 18F-FDG PET/CT was preferred consideration and no serious complications were noted. Meanwhile, an adequate amount of tissue is required for immunophenotyping and genetic testing to establish a definitive diagnosis of lymphomas [29]. In our study, an adequate amount of tissue was obtained in all 34 patients and definitive subtype diagnosis was determined in 31 of 34 patients. The overall success rate was 91.2%. The remaining two patients were diagnosed with B-cell lymphomas, and didn’t receive immunophenotyping and genetic testing for differential diagnosis due to lack of funds. Thus, our biopsy procedure actually showed a safe, feasible and effective method for diagnosis of lymphomas. When an FDG-avid peripheral lymph node is not present, or in the case of primary bone

---

**Fig. 4** A patient with mixed cell Hodgkin lymphoma, who was suspected of having multifocal bone lesions on the PET/CT image. Targeted biopsy confirmed false-positive PET findings. a MIP image showed multifocal bone lesions. b and c Axial CT image, axial PET/CT fusion image, showed high $^{18}$F-FDG uptake within the right ilium (white arrow) and osteolytic destruction was observed within the corresponding hypermetabolic region (white arrow). d CT image showed the biopsy needle positioned within the right ilium lesion (arrow). e Histological examination combined with immunohistochemical result confirmed the diagnosis of eosinophilic granuloma with fibrosis.
Fig. 5 A patient who was suspected of having a lymphoma based on $^{18}$F-FDG PET/CT findings. Both diagnosis and staging were completed through PET/CT-guided targeted bone marrow biopsy in one procedure. The iliac crest biopsy was negative. 

a MIP image showed high $^{18}$F-FDG uptake within lesions in multiple retroperitoneal lymph nodes, spleen, and isolated left ilium. 

b and c PET/CT image showed high $^{18}$F-FDG uptake (SUVmax 3.38) within the left ilium, while no abnormality was observed on corresponding CT image (arrow). 

d CT image showed the biopsy needle positioned within the left ilium lesion (arrow). 

e Histological examination combined with immunohistochemical result confirmed a diagnosis of DLBCL.

Fig. 6 A patient with suspected lymphoma involvement in multiple areas of bone marrow, liver, spleen, and lymph nodes. She received targeted biopsy for diagnosis and staging. 

a MIP image showed high $^{18}$F-FDG uptake within lesions in the bone marrow, liver, spleen, and lymph nodes. 

b and c Axial PET/CT image showed high $^{18}$F-FDG uptake (SUVmax 17.34) within the left ilium, and abnormality on the corresponding CT image (arrow). 

d CT image showed the biopsy needle positioned within the left ilium lesion (arrow). 

e Histological examination combined with immunohistochemical result confirmed a diagnosis of DLBCL. 

f MIP of follow-up $^{18}$F-FDG PET/CT at the end of chemotherapy showed no hypermetabolic lesions (complete response).
lymphoma, a targeted BMB is a potential alternative for accurate diagnosis, and complete staging in a single procedure. However, targeted bone marrow biopsy in some localizations may be relatively difficult, such as skull, anterior part of vertebra etc. The puncture site should be selected in the relatively safe localizations for avoiding serious complication.

Diffuse bone lesions on PET/CT scan are usually defined as homogeneous increased FDG uptake of the entire axial skeleton, and are a well-known phenomenon in patients treated with hematopoietic growth factors [34, 35]. However, the finding is relatively uncommon in newly diagnosed lymphomas [36]. In a study by Adams et al. [37], the incidence of diffuse bone lesions on PET/CT scan was 4.2% (23/542), and the frequency of positive iliac crest biopsies was 55.0% (11/20) in newly diagnosed lymphomas. But our current study reported that the incidences of diffuse skeletal uptake were about 17.4%. The difference in the incidences is due to the different PET positive standard. We considered 18F-FDG FDG uptake greater the mediastinum as PET positive standard, while Hugo J.A. Adams refer to 18F-FDG FDG uptake greater than liver. Thus, it is explainable why the incidence of diffuse bone marrow FDG uptake in our current study was higher than that of Hugo J.A. Adams's results. This present study showed that 18F-FDG PET/CT does not exhibit very good concordance with the results of iliac crest biopsy, and its sensitivity and specificity were only 56 and 83%, respectively. Thus, iliac crest biopsy is more useful for diffuse bone lesions seen on PET/CT scan compared with other modality.

A routine iliac crest biopsy also cannot be safely omitted in the case of negative bone marrow PET/CT findings, except in cases of DLBCL [14, 19].In our study, we did not find positive iliac crest biopsy results if the PET/CT was negative in patients with DLBCL. But in other subtypes of lymphomas, of 164 patients who had negative PET/CT results, 17 had positive iliac crest results, resulting in an overall NPV of 90%. Thus, 10% of the patients would be inaccurate staging if the iliac crest biopsy was not performed.

Some limitations of this study should be acknowledged. First, the sample size of PET/CT-guided targeted BMBs was limited. We tried to retrieve multi-center data to test and verify our results. Second, only 18F-FDG PET/CT and iliac crest biopsy were studied, more other modality, such as MRI, laboratory examination, etc. must be considered. Finally, subtypes of lymphomas present differences depending on various PET/CT findings. In regard to these problems, more studies will be followed in the future gradually.

**Conclusion**

It is insufficient to evaluate BMI in newly diagnosed lymphomas using both 18F-FDG PET/CT and routine iliac crest biopsy. It is recommended that 18F-FDG PET/CT imaging be performed before any BMB. In focal lesions identified on 18F-FDG PET/CT scan, it is preferable to PET/CT-guided targeted biopsy, because it could not exclude possible false-positive PET/CT findings, even in HL, and can also avoid additional blind biopsies. However, in diffuse and negative lesions identified on 18F-FDG PET/CT scan, iliac crest biopsy cannot be safely omitted.

**Abbreviations**

- 95%CI: 95% confidence interval
- BM: Bone marrow
- BMI: Bone marrow involvement
- DLBCL: Diffuse large B-cell lymphoma
- HL: Hodgkin lymphoma
- MALT: Mucosa-associated lymphoid tissue
- MDS: Myelodysplastic syndrome
- NCCN: National Comprehensive Cancer Network
- NHL: Non-Hodgkin lymphomas
- NPV: Negative predictive value
- PPV: Positive predictive value
- SLI/CLL: Small lymphocytic lymphoma/chronic lymphocytic leukemia

**Acknowledgements**

We are indebted to Nuclear department & Minnan PET Center of Fujian Province for providing technical assistance. We also thank all the patients for allowing us to analyze their data.

**Funding**

This study was funded by the National Natural Science Foundation of China (81101067), the Natural Science Foundation of Fujian Province of China (2015 J01543) and the second batch of science and technology projects in Xiamen (3502Z20164011). Funding bodies were not involved in the design of the study, collection, analysis, and interpretation of date or in writing the manuscript.

**Availability of data and materials**

The datasets and materials used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

BH, LZ, LS carried out conception and design. BH, LZ, WG, NL, HF, YP, HC, JW carried out collection and assembly of data. BH, LZ, XG, DR and ZL carried out data analysis and interpretation. JW, DR and XG carried out PET/CT acquisition and collection of clinical data. HW, LS and LZ provided critical comments for this manuscript. BH, LZ, YP, HW and LS participated in manuscript writing and revision. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

The study was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Xiamen University, Xiamen, China (KYX-2012 012). Written informed consent was obtained from each participant.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Received** 9 July 2018 **Accepted** 16 November 2018

**Published online** 29 November 2018

**References**

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2015;66(2):115–32.
2. Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin’s lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska lymphoma study group. J Clin Oncol. 1990;8(7):1163–72.
3. Munker R, Hasenclever D, Brosteanu O, Hillek E, Diehl V. Bone marrow involvement in Hodgkin’s disease: an analysis of 135 consecutive cases. German Hodgkin’s lymphoma study group. J Clin Oncol. 1995;13(2):403–9.

4. Brunning RD, Bloomfield CD, McKenna RW, Peterson LA. Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med. 1975;83(3):365–6.

5. Jungeja SK, Wolff MM, Cooper IA. Value of bilateral bone marrow biopsy specimens in non-Hodgkin’s lymphoma. J Clin Pathol. 1990;43(8):630–2.

6. Wang J, Weiss LM, Chang KL, Slovak ML, Gaal K, Forman SJ, Arber DA. Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer. 2002;94(5):1522–31.

7. Bitunetti GA, Tendas A, Meloni E, Mancini D, Maggiori P, Sacramucci L, Giovannini M, Nicola P, Cartoni C, Almena G. Pain and anxiety associated with bone marrow aspiration and biopsy: a prospective study on 152 Italian patients with hematological malignancies. Ann Hematol. 2001;80(10):233–3.

8. Bain BJ. Morbidity associated with bone marrow aspiration and trephine biopsy - a review of UK data for 2004. Haematologica. 2006;91(1):293–4.

9. Carr R, Barrington SF, Madan B, O’Doherty MJ, Saunders CA, van der Walt J, YP, Han WE. Preliminary evaluation of PET-CT and DWI for the detection of lymphoma bone marrow infiltration. Zhonghua Zhong Liu Za Zhi. 2016;38(11):853–60.

10. Chowdhury FU, Shuh N, Scarsbrook AF, Bradley KM. [18F]FDG PET/CT imaging of colorectal cancer: a pictorial review. Postgrad Med J. 2010;86(1031):174–82.

11. Hao B, Guo W, Luo NN, Fu H, Chen HJ, Zhao L, Wu H, Sun L. Metabolic imaging for guidance of curative treatment of isolated pelvic implantation metastasis after resection of spontaneously ruptured hepatocellular carcinoma: a case report. World J Gastroenterol. 2016;22(41):9242–6.

12. Comelis F, Silk M, Schoder H, Takaki H, Durack JC, Einrinji JP, Sofoctie CT, Siegelbaum RH, Maybody M, Solomon SB. Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities. Eur J Nucl Med Mol Imaging. 2014;41(12):2265–72.

13. Kaeser B, Wilschken J, Wartenberg J, Weizel T, Schmid RA, Mueller KD, Krause T. PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact. Eur J Nucl Med Mol Imaging. 2010;37(11):2027–36.

14. Horwitz SM, Zeleknetz AD, Gordon LL, Wierda WG, Abrams J, Advani RH, Andreiadis CB, Barthet N, Byrd JC, Fayad LE, et al. NCCN guidelines insights: non-Hodgkin’s lymphomas, version 3.2016. J Natl Compr Canc Netw. 2016;14(9):1067–79.

15. Adams HJ, Nievelstein RA, Kwee TC. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma. Blood. 2015;129(6):417–25.

16. Matti A, Farolfi A, Frisoni T, Fanti S, Nanni C. FDG-PET/CT guided biopsy in Angiosarcoma of bone diagnosis, staging and beyond. Clin Nucl Med. 2018;43(2):e48–9.

17. Adams HJ, de Kerk JM, Heggelman BG, Dubois SV, Kwee TC. Malignancy rate of biopsied suspicious bone lesions identified on FDG PET/CT. Eur J Nucl Med Mol Imaging. 2016;43(7):1231–8.

18. Maciel MJ, Tyng CJ, Barbosa PN, Bittencourt AG, Matsuhashi Junior JP, Zurrianess CE, Chung WT, Choiyaj R. Computed tomography-guided percutaneous biopsy of bone lesions: rate of diagnostic success and complications. Radiol Bras. 2014;47(5):269–74.

19. Knopp MV, Bischoff H, Rimacl A, Oderdorfer F, van Kaick G. Bone marrow uptake of Fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: initial evaluation. Nucl Med Biol. 1996;23(6):845–9.

20. Hollinger EF, Albazoglu H, Ali A, Green A, Lamonica G. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med. 1998;23(2):93–8.

21. Khan AB, Barrington SF, Mikaheal NG, Hunt AA, Cameron L, Morris T, Carr R. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013;122(1):161–7.

22. Adams HJ, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RA, de Kerk JM. Diffusely increased bone marrow FDG uptake in recurrent, unmetastatic lymphoma: incidence and relevance. Eur J Haematol. 2015;95(1):83–9.